|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,400.00 JPY | +2.51% |
|
+2.17% | +14.04% |
| 02-06 | Japan's Nikkei rallies on earnings in unsteady trade before Sunday election | RE |
| 02-06 | Japanese drugmakers slump after Trump unveils discount drug website | RE |
Business description: Chugai Pharmaceutical Co., Ltd.
Number of employees: 5,026
Sales by Activity: Chugai Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2020 (JPY) | 2021 (JPY) | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) |
|---|---|---|---|---|---|
Pharmaceuticals | 787B | 1T | 1,260B | 1,111B | 1,171B |
Geographical breakdown of sales: Chugai Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2020 (JPY) | 2021 (JPY) | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) |
|---|---|---|---|---|---|
Overseas | - | - | - | - | 537B |
Japan | 419B | 522B | 657B | 559B | 461B |
Unallocated | - | - | - | - | 173B |
Other Overseas | 20.4B | 27.14B | 120B | 40.25B | - |
Switzerland | 348B | 450B | 483B | 512B | - |
Executive Committee: Chugai Pharmaceutical Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 62 | 31/12/2020 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | - | 27/03/2024 |
Junichi Nezu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Hisafumi Okabe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Motoo Ueno
AUD | Comptroller/Controller/Auditor | 68 | 29/02/2004 |
Composition of the Board of Directors: Chugai Pharmaceutical Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Motoo Ueno
BRD | Director/Board Member | 68 | 28/02/1993 |
Masayuki Oku
BRD | Director/Board Member | 81 | 28/02/2015 |
| Director/Board Member | 77 | 28/02/2017 | |
Christoph Franz
BRD | Director/Board Member | 65 | 28/02/2017 |
William Anderson
BRD | Director/Board Member | 59 | 28/02/2019 |
James H. Sabry
BRD | Director/Board Member | 67 | 28/02/2019 |
Osamu Okuda
BRD | Director/Board Member | 62 | 29/02/2020 |
Mariko Momoi
BRD | Director/Board Member | 78 | 29/02/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | - | 27/03/2024 |
| Director/Board Member | 51 | - |
Holdings: Chugai Pharmaceutical Co., Ltd.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 33,354,300 | 1.99% | 1 903 M $ |
Company details: Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Nihonbashi Mitsui Tower, 15/F
103-8324, Tokyo
+81 3 3281 6611
https://www.chugai-pharm.co.jp
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.51% | +2.17% | +26.96% | +163.31% | 98.24B | |
| -0.38% | +1.08% | +22.72% | +215.48% | 926B | |
| -0.05% | +2.09% | +55.83% | +51.71% | 586B | |
| +0.59% | +4.68% | +20.73% | +53.90% | 412B | |
| +0.05% | +3.64% | +25.40% | +32.05% | 382B | |
| +0.92% | +5.76% | +32.94% | +35.80% | 326B | |
| +0.54% | +4.92% | +34.30% | +61.73% | 317B | |
| +0.13% | +3.77% | +46.45% | +11.00% | 302B | |
| -0.15% | +0.88% | -47.29% | -37.09% | 218B | |
| +1.13% | +2.39% | +28.23% | +55.22% | 201B | |
| Average | +0.34% | +3.00% | +24.63% | +64.31% | 376.74B | |
| Weighted average by Cap. | +0.19% | +2.91% | +28.04% | +84.36% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4519 Stock
- Company Chugai Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition